79
+8%
4,378 $m
Johnson & Johnson
Johnson & Johnson (J&J) rebounded strong in 2012, demonstrating the resilience of its brand. Alex Gorsky, a J&J veteran very familiar with the safety and quality issues that have plagued the company in the recent past, was named CEO. While safety and quality issues like supply shortages and recalls of Tylenol products continued in 2012, J&J’s responsiveness in updating safety protocols, and its commitment to social responsibility have enabled the company to bounce back — and establish itself once again as a trusted corporate brand. J&J continues to expand its consumer health presence in emerging markets. Outside of the consumer health space, J&J continues to grow its presence and influence. Most apparent is the Medical Device and Diagnostic division’s acquisition of Synthes, a leading global medical device company. By merging Synthes with its DePuy franchise to form the new DePuy Synthes Companies, J&J has created the world’s largest, most innovative orthopedic and neurological business. Driven by its credo to improve the health and well-being of people around the world, J&J continues to demonstrate that a strong brand can help a company weather all storms.